Ricky A Sharma

Summary

Affiliation: University of Leicester
Country: UK

Publications

  1. ncbi Curcumin: the story so far
    R A Sharma
    Cancer Biomarkers and Prevention Group, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester Royal Infirmary, Leicester LE2 7LX, UK
    Eur J Cancer 41:1955-68. 2005
  2. ncbi Colorectal cancer chemoprevention: biochemical targets and clinical development of promising agents
    R A Sharma
    University Department of Oncology, Leicester Royal Infirmary, LE1 5WW, Leicester, UK
    Eur J Cancer 37:12-22. 2001
  3. ncbi Neuron-specific enolase expression in multiple myeloma
    Ricky A Sharma
    Department of Radiotherapy, Royal Marsden Hospital, London, UK
    Lancet Oncol 7:960. 2006
  4. ncbi Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies
    R A Sharma
    Department of Radiotherapy, Royal Marsden Hospital NHS Foundation Trust, Downs Road, Sutton, Surrey London, SM2 5PT, UK
    Eur J Cancer 42:2318-25. 2006
  5. ncbi Mechanisms of the self/non-self-survey in the defense against cancer: potential for chemoprevention?
    Ricky A Sharma
    Radiotherapy Department, Royal Marsden Hospital NHS Trust, Downs Road, Sutton SM2 5PT, UK
    Crit Rev Oncol Hematol 56:5-22. 2005
  6. ncbi Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance
    Ricky A Sharma
    Oncology Department, University of Leicester, Leicester, United Kingdom
    Clin Cancer Res 10:6847-54. 2004
  7. ncbi Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy
    Ricky A Sharma
    Department of Oncology, Leicester Royal Infirmary, University Hospitals of Leicester, Leicester, LE1 5WW, UK
    Cancer Chemother Pharmacol 52:367-70. 2003
  8. ncbi Angiogenesis and the immune response as targets for the prevention and treatment of colorectal cancer (review)
    Ricky A Sharma
    University Department of Oncology, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Oncol Rep 10:1625-31. 2003
  9. ncbi Completion of the audit cycle: standardised nurse-led information for patients
    R A Sharma
    Oncology Department, University Hospitals of Leicester, Leicester Royal Infirmary, UK
    Postgrad Med J 79:652-4. 2003
  10. ncbi Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer
    R A Sharma
    Oncology Department, University of Leicester, Leicester Royal Infirmary, UK
    QJM 95:267-73. 2002

Detail Information

Publications43

  1. ncbi Curcumin: the story so far
    R A Sharma
    Cancer Biomarkers and Prevention Group, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester Royal Infirmary, Leicester LE2 7LX, UK
    Eur J Cancer 41:1955-68. 2005
    ..Sufficient data currently exist to advocate phase II clinical evaluation of oral curcumin in patients with invasive malignancy or pre-invasive lesions of the gastrointestinal tract, particularly the colon and rectum...
  2. ncbi Colorectal cancer chemoprevention: biochemical targets and clinical development of promising agents
    R A Sharma
    University Department of Oncology, Leicester Royal Infirmary, LE1 5WW, Leicester, UK
    Eur J Cancer 37:12-22. 2001
    ....
  3. ncbi Neuron-specific enolase expression in multiple myeloma
    Ricky A Sharma
    Department of Radiotherapy, Royal Marsden Hospital, London, UK
    Lancet Oncol 7:960. 2006
  4. ncbi Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies
    R A Sharma
    Department of Radiotherapy, Royal Marsden Hospital NHS Foundation Trust, Downs Road, Sutton, Surrey London, SM2 5PT, UK
    Eur J Cancer 42:2318-25. 2006
    ..Depending on the extent of myelosuppressive pre-treatment, dose schedules (II) or (III) are advocated for large-scale trials of long-term administration...
  5. ncbi Mechanisms of the self/non-self-survey in the defense against cancer: potential for chemoprevention?
    Ricky A Sharma
    Radiotherapy Department, Royal Marsden Hospital NHS Trust, Downs Road, Sutton SM2 5PT, UK
    Crit Rev Oncol Hematol 56:5-22. 2005
    ..Interventional strategies may involve the use of pro-differentiation agents such as retinoids, modifiers of polyamine biosynthesis or inhibitors of cyclooxygenase isozymes...
  6. ncbi Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance
    Ricky A Sharma
    Oncology Department, University of Leicester, Leicester, United Kingdom
    Clin Cancer Res 10:6847-54. 2004
    ..PGE(2) production in blood and target tissue may indicate biological activity. Levels of curcumin and its metabolites in the urine can be used to assess general compliance...
  7. ncbi Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy
    Ricky A Sharma
    Department of Oncology, Leicester Royal Infirmary, University Hospitals of Leicester, Leicester, LE1 5WW, UK
    Cancer Chemother Pharmacol 52:367-70. 2003
    ..Since treatment with many chemotherapeutic agents is relatively contraindicated, we assessed the safety, tolerability and potential efficacy of combination chemotherapy with vinorelbine and cisplatin (ViP)...
  8. ncbi Angiogenesis and the immune response as targets for the prevention and treatment of colorectal cancer (review)
    Ricky A Sharma
    University Department of Oncology, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Oncol Rep 10:1625-31. 2003
    ..It is proposed that intervention to prevent or treat colorectal cancer should be targeted at inhibiting inflammation, reducing angiogenesis and stimulating cell mediated immune responses...
  9. ncbi Completion of the audit cycle: standardised nurse-led information for patients
    R A Sharma
    Oncology Department, University Hospitals of Leicester, Leicester Royal Infirmary, UK
    Postgrad Med J 79:652-4. 2003
    ..It is not yet clear what form such information should take...
  10. ncbi Translational medicine: targetting cyclo-oxygenase isozymes to prevent cancer
    R A Sharma
    Oncology Department, University of Leicester, Leicester Royal Infirmary, UK
    QJM 95:267-73. 2002
  11. ncbi Biological relevance of adduct detection to the chemoprevention of cancer
    Ricky A Sharma
    Cancer Biomarkers and Prevention Group, Oncology Department, University of Leicester, Leicester Royal Infirmary, Leicester, United Kingdom
    Clin Cancer Res 10:4901-12. 2004
    ..quot;We do not administer antihypertensive drugs to patients in clinical trials without checking their blood pressure, so why should we give antioxidants without checking that they have decreased oxidant status...
  12. ncbi Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer
    R A Sharma
    Oncology Department, University of Leicester, Leicester LE1 9HN, United Kingdom
    Clin Cancer Res 7:1894-900. 2001
    ..2 g daily, equivalent to 180 mg of curcumin; (b) curcumin has low oral bioavailability in humans and may undergo intestinal metabolism; and (c) larger clinical trials of Curcuma extract are merited...
  13. ncbi Familiar drugs may prevent cancer
    R A Sharma
    Oncology Department, University of Leicester, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Postgrad Med J 77:492-7. 2001
    ..Practitioners should be amenable to patient referral to discuss complex issues such as risk estimation or potential benefit from intervention...
  14. ncbi Cyclooxygenase-2, malondialdehyde and pyrimidopurinone adducts of deoxyguanosine in human colon cells
    R A Sharma
    Oncology Department and MRC Toxicology Unit, University of Leicester, Leicester LE1 9HN, UK
    Carcinogenesis 22:1557-60. 2001
    ..Moreover, they demonstrate the correlation between MDA concentration and M(1)G adduct levels in malignant cells...
  15. ncbi Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver
    R A Sharma
    University Department of Oncology, Leicester Royal Infirmary, UK
    Cancer Chemother Pharmacol 48:197-201. 2001
    ..The aim of this study was to assess the systemic bioavailability of this rationally designed drug in 16 patients with advanced solid cancers...
  16. ncbi Involving patients in treatment decisions: can we learn from clinical trials?
    R A Sharma
    Leicester Royal Infirmary, UK
    Clin Oncol (R Coll Radiol) 13:328-32. 2001
    ..If greater patient participation in treatment decisions is advocated, more written and verbal information and closer involvement of hospital nurses should be considered for all forms of chemotherapy...
  17. ncbi The advancement of cancer chemoprevention by revision of clinical trial strategies
    R A Sharma
    Cancer Biomarkers and Prevention Group, Oncology Department, University of Leicester, Leicester, UK
    Panminerva Med 44:41-5. 2002
    ..This structured approach currently emerging is providing pharmacological and mechanistic data on novel agents which will prove essential in the planning of larger-scale commitments...
  18. ncbi Angiogenesis as a biomarker and target in cancer chemoprevention
    R A Sharma
    Department of Oncology, University of Leicester Royal Infirmary, UK
    Lancet Oncol 2:726-32. 2001
    ..Validation of angiogenesis as a biomarker for the effectiveness of chemoprevention should further the advancement of some chemopreventive agents...
  19. ncbi Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences
    Giuseppe Garcea
    Department of Oncology, RKCSB, LRI, University of Leicester, Leicester, LE2 7LX, United Kingdom
    Cancer Epidemiol Biomarkers Prev 14:120-5. 2005
    ..The results suggest that a daily dose of 3.6 g curcumin achieves pharmacologically efficacious levels in the colorectum with negligible distribution of curcumin outside the gut...
  20. ncbi Simultaneous determination of 8-oxo-2'-deoxyguanosine and 8-oxo-2'-deoxyadenosine in DNA using online column-switching liquid chromatography/tandem mass spectrometry
    Rajinder Singh
    Biocentre, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester, UK
    Rapid Commun Mass Spectrom 23:151-60. 2009
    ....
  21. ncbi Clinical development of leukocyte cyclooxygenase 2 activity as a systemic biomarker for cancer chemopreventive agents
    S M Plummer
    MRC Toxicology Unit, University of Leicester, Leicester LE1 9HN, United Kingdom
    Cancer Epidemiol Biomarkers Prev 10:1295-9. 2001
    ..Measurement of leukocyte COX-2 activity should be considered in clinical trials of other agents likely to inhibit this isozyme...
  22. ncbi Androgen manipulation alters oxidative DNA adduct levels in androgen-sensitive prostate cancer cells grown in vitro and in vivo
    Sanjeev Pathak
    Cancer Biomarkers and Prevention Group, Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester LE2 7LX, UK
    Cancer Lett 261:74-83. 2008
    ..001 by Mann-Whitney Test) in flutamide-treated animals compared to controls. The changes demonstrated suggest that oxidative DNA adducts may serve as biomarkers of the efficacy of androgen manipulation in chemoprevention trials...
  23. ncbi Cancer prevention and delay are as important as cure
    Andreas J Gescher
    Cancer Biomarkers and Prevention Group, Department of Oncology, University of Leicester, Leicester, LE2 7LX, UK
    Lancet Oncol 4:72-3. 2003
  24. ncbi Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis
    Sarah Perkins
    Cancer Biomarkers and Prevention Group, Department of Oncology, University of Leicester, Leicester, United Kingdom
    Cancer Epidemiol Biomarkers Prev 11:535-40. 2002
    ..6 g of curcumin is required for efficacy in humans. A clear advantage of curcumin over nonsteroidal anti-inflammatory drugs is its ability to decrease intestinal bleeding linked to adenoma maturation...
  25. ncbi Molecular biomarkers of colorectal carcinogenesis and their role in surveillance and early intervention
    G Garcea
    University Department of Oncology, 5th Floor, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, UK
    Eur J Cancer 39:1041-52. 2003
    ..Research should be directed at assessing complementary biomarkers to increase clinical effectiveness in determining management options for patients...
  26. ncbi Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration
    G Garcea
    Cancer Biomarkers and Prevention Group, Department of Cancer Studies and Biochemistry, University of Leicester, 5th Floor Robert Kilpatrick Clinical Sciences Building, Leicester LE2 7LX, UK
    Br J Cancer 90:1011-5. 2004
    ..The results suggest that doses of curcumin required to furnish hepatic levels sufficient to exert pharmacological activity are probably not feasible in humans...
  27. ncbi Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels
    R A Sharma
    Department of Oncology, University of Leicester, Leicester LE1 9HN, United
    Clin Cancer Res 7:1452-8. 2001
    ....
  28. ncbi Cancer chemoprevention by dietary constituents: a tale of failure and promise
    A J Gescher
    Department of Oncology, University of Leicester, UK
    Lancet Oncol 2:371-9. 2001
    ..Pilot clinical trials on the pharmacokinetics and mechanism-based markers of efficacy of the selected intervention should precede phase I-III development in suitable populations...
  29. ncbi Biological relevance of DNA polymerase β and translesion synthesis polymerases to cancer and its treatment
    Nils H Nicolay
    Cancer Research UK Medical Research Council Gray Institute, Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK
    Curr Mol Pharmacol 5:54-67. 2012
    ..The potential clinical role of new DNA polymerase inhibitors is discussed and how they may be combined with conventional cytotoxic agents...
  30. ncbi Oxidative stress and cyclooxygenase activity in prostate carcinogenesis: targets for chemopreventive strategies
    S K Pathak
    Division of Urology, Clinical Sciences Unit, Leicester General Hospital, University of Leicester, Gwendolen Road, Leicester LE5 4PW, UK
    Eur J Cancer 41:61-70. 2005
    ..A greater understanding of the molecular events associated with oxidative stress will enhance the development of such biomarkers and should result in better strategies for the chemoprevention of prostate cancer...
  31. ncbi Oxaliplatin as a radiosensitiser for upper and lower gastrointestinal tract malignancies: what have we learned from a decade of translational research?
    Esme J Hill
    Gray Institute of Radiation Oncology and Biology, Oncology Department, Old Road Campus Research Building, Oxford OX3 7DQ, UK
    Crit Rev Oncol Hematol 83:353-87. 2012
    ....
  32. ncbi Intra-arterial brachytherapy of hepatic malignancies: watch the flow
    Bruno Morgan
    Department of Cancer Studies and Molecular Medicine, University of Leicester, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Nat Rev Clin Oncol 8:115-20. 2011
    ..We propose dynamic contrast-enhanced CT as the most appropriate imaging modality for studying vascular parameters in clinical trials of RE treatment...
  33. ncbi Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy
    C M Richardson
    Department of Oncology, University of Leicester, Osborne Building, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester LEI 5WW, UK
    Lung Cancer 39:1-13. 2003
    ..An increasing body of evidence suggests that selective inhibitors of both EGFR and COX-2 are potential therapeutic agents for the treatment of NSCLC, in the adjuvant, metastatic and chemopreventative settings...
  34. ncbi Chemoprevention of prostate cancer by diet-derived antioxidant agents and hormonal manipulation (Review)
    S K Pathak
    Cancer Biomarkers and Prevention Group, Department of Oncology, University of Leicester, Leicester, LE2 7LX, UK
    Int J Oncol 22:5-13. 2003
    ..In parallel, reliable assays of potential biomarkers of the efficacy of intervention need to be developed and validated rigorously...
  35. ncbi Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials
    Alexios S Strimpakos
    Department of Medicine, Royal Marsden Hospital, London, England
    Antioxid Redox Signal 10:511-45. 2008
    ..Despite the breadth of the coverage, particular emphasis is placed on the prevention and treatment of human cancers...
  36. ncbi Cyclooxygenase-2 expression and oxidative DNA adducts in murine intestinal adenomas: modification by dietary curcumin and implications for clinical trials
    R G Tunstall
    Cancer Biomarkers and Prevention Group, Departments of Cancer Studies and Biochemistry, University of Leicester, Leicester LE2 7LX, UK
    Eur J Cancer 42:415-21. 2006
    ..The effects of long-term dietary curcumin on COX-2 protein levels appear to reflect retardation of adenoma development...
  37. ncbi Challenges in treating patients with Down's syndrome and testicular cancer with chemotherapy and radiotherapy: The Royal Marsden experience
    S Hafeez
    Radiotherapy Department, Royal Marsden Hospital NHS Trust, Downs Road, Sutton, Surrey SM2 5PT, UK
    Clin Oncol (R Coll Radiol) 19:135-42. 2007
    ..We aimed to identify and discuss management challenges in the treatment of these patients with chemotherapy and radiotherapy and report their clinical outcome...
  38. ncbi A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer
    K J O'Byrne
    University Department of Oncology, Osborne Building, Leicester Royal Infirmary, Leicester LE1 5WW, UK
    Br J Cancer 87:15-20. 2002
    ....
  39. ncbi DNA repair pathways as targets for cancer therapy
    Thomas Helleday
    Radiation Oncology and Biology, University of Oxford, Old Road Campus Research Building, off Roosevelt Drive, Headington, Oxford, OX3 7DQ, UK
    Nat Rev Cancer 8:193-204. 2008
    ....
  40. ncbi Targeting base excision repair to improve cancer therapies
    Ricky A Sharma
    Radiation Oncology and Biology, University of Oxford, Churchill Hospital, Oxford OX3 7LJ, UK
    Mol Aspects Med 28:345-74. 2007
    ..It is anticipated that the application of this knowledge will translate into the development of novel effective therapies for improving existing treatments such as radiation therapy and oxaliplatin chemotherapy...
  41. ncbi Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy
    Ricky A Sharma
    Department of Radiation Oncology and Biology, University of Oxford, Churchill Hospital, Oxford, UK
    J Clin Oncol 25:1099-106. 2007
    ..This treatment has not been tested with the radiosensitizing chemotherapy, oxaliplatin, which appears synergistic in the treatment of CRC when combined with fluorouracil and leucovorin (FOLFOX)...
  42. ncbi Pharmacokinetics and pharmacodynamics of curcumin
    Ricky A Sharma
    Radiation Oncology and Biology, University of Oxford, Churchill Hospital, UK
    Adv Exp Med Biol 595:453-70. 2007
    ..With regard to considerable public and scientific interest in the use of phytochemicals derived from dietary components to combat or prevent human diseases, curcumin is currently a leading agent...
  43. ncbi Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium
    Andrew Kennedy
    Wake Radiology Oncology, Cary, NC, USA
    Int J Radiat Oncol Biol Phys 68:13-23. 2007
    ..To standardize the indications, techniques, multimodality treatment approaches, and dosimetry to be used for yttrium-90 (Y90) microsphere hepatic brachytherapy...